Bajh.Ns
BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
Business. BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
BAJH.NS operates in the pharmaceuticals industry, developing and commercializing prescription drugs and therapies for various medical conditions.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the industry median of 0.65, indicating a lower reliance on debt financing. Free cash flow of INR 565.5 million supports operational flexibility, though operating cash flow of INR 216.2 million is modest relative to total liabilities of INR 3.7 billion. The current ratio of 1.89 suggests adequate short-term liquidity, though the risk assessment flags net cash as negative after subtracting total debt.
Profitability metrics show a return on equity of 8.47% and a return on assets of 4.74%, both below the industry median of 10.2% and 6.1%, respectively. Gross profit of INR 2.6 billion represents 47.2% of revenue, which is in line with the industry average, but operating income of INR 576.1 million reflects a 10.6% margin, below the median of 12.3%.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic or regulatory shifts. No material revenue is attributed to international markets, suggesting a domestic focus.
Outlook data indicates a projected 12.3% year-over-year revenue growth for the current fiscal year, driven by new product launches and market expansion. The next fiscal year is expected to see a 9.8% growth, though this is slightly below the industry median of 11.5%. Historical revenue growth has averaged 8.7% annually over the past five years.
Risk factors include medium liquidity risk due to the negative net cash position and a current ratio that, while acceptable, does not provide a large buffer against short-term obligations. Dilution risk is assessed as low, with no recent share issuance and no material dilution expected in the near term. No significant regulatory or geopolitical risks are currently flagged.
Recent filings and transcripts have not disclosed any material events that would significantly alter the company's strategic direction or financial outlook.
- BAJH.NS maintains a conservative capital structure with a debt-to-equity ratio of 0.48, below the industry median.
- Return on equity of 8.47% and return on assets of 4.74% indicate below-median profitability.
- Revenue is concentrated in a single business segment with no disclosed geographic diversification.
- Outlook projects 12.3% revenue growth for the current fiscal year, driven by new product launches.
- Liquidity risk is moderate due to a negative net cash position, though the current ratio remains acceptable.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- BAJH.NS Market data — financials · 2026-05-27